Format

Send to

Choose Destination
Am J Clin Oncol. 1993 Dec;16(6):526-8.

Multicenter phase II study of brequinar sodium in patients with advanced breast cancer.

Author information

1
University of Michigan, Ann Arbor.

Abstract

In this study, 34 patients with advanced breast cancer were treated with brequinar sodium: 75% of the patients were postmenopausal, and 94% had received chemotherapy previously; 50% had previously received an anthracycline-containing regimen. Brequinar was administered intravenously at a median weekly dose of 1,200 mg/m2. The toxicity was moderate, with 17 patients (50%) experiencing grade 3 or 4 toxicity. There were 33 patients evaluable for response: 4 patients (12%; 95% confidence interval, 3.4-28.2%) achieved partial responses, 10 patients (30%) were stable, and 19 patients (58%) had progressive disease. We conclude that, at this dose and schedule, brequinar has only modest activity in patients with advanced breast cancer.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center